These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 8279223)

  • 1. Growth hormone-releasing activity of growth hormone-releasing peptide-1 (a synthetic heptapeptide) in children and adolescents.
    Laron Z; Bowers CY; Hirsch D; Almonte AS; Pelz M; Keret R; Gil-Ad I
    Acta Endocrinol (Copenh); 1993 Nov; 129(5):424-6. PubMed ID: 8279223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pituitary responsiveness to GH-releasing hormone, GH-releasing peptide-2 and thyrotrophin-releasing hormone in critical illness.
    Van den Berghe G; de Zegher F; Bowers CY; Wouters P; Muller P; Soetens F; Vlasselaers D; Schetz M; Verwaest C; Lauwers P; Bouillon R
    Clin Endocrinol (Oxf); 1996 Sep; 45(3):341-51. PubMed ID: 8949573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone.
    Bowers CY; Reynolds GA; Durham D; Barrera CM; Pezzoli SS; Thorner MO
    J Clin Endocrinol Metab; 1990 Apr; 70(4):975-82. PubMed ID: 2108187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intranasal administration of His-D-Trp-Ala-Trp-D-Phe-LysNH2 (growth hormone releasing peptide) increased plasma growth hormone and insulin-like growth factor-I levels in normal men.
    Hayashi S; Okimura Y; Yagi H; Uchiyama T; Takeshima Y; Shakutsui S; Oohashi S; Bowers CY; Chihara K
    Endocrinol Jpn; 1991 Feb; 38(1):15-21. PubMed ID: 1915110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic studies with intravenous and intranasal growth hormone-releasing peptide-2 in children of short stature.
    Pihoker C; Middleton R; Reynolds GA; Bowers CY; Badger TM
    J Clin Endocrinol Metab; 1995 Oct; 80(10):2987-92. PubMed ID: 7559885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of a prolonged growth hormone (GH)-releasing peptide infusion on pulsatile GH secretion in normal men.
    Jaffe CA; Ho PJ; Demott-Friberg R; Bowers CY; Barkan AL
    J Clin Endocrinol Metab; 1993 Dec; 77(6):1641-7. PubMed ID: 7903313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute growth hormone (GH) response to GH-releasing hexapeptide in humans is independent of endogenous GH-releasing hormone.
    Robinson BM; Friberg RD; Bowers CY; Barkan AL
    J Clin Endocrinol Metab; 1992 Oct; 75(4):1121-4. PubMed ID: 1400881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth hormone-releasing effect of oral growth hormone-releasing peptide 6 (GHRP-6) administration in children with short stature.
    Bellone J; Ghizzoni L; Aimaretti G; Volta C; Boghen MF; Bernasconi S; Ghigo E
    Eur J Endocrinol; 1995 Oct; 133(4):425-9. PubMed ID: 7581965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, in short normal and obese children and in hypopituitary subjects.
    Loche S; Cambiaso P; Carta D; Setzu S; Imbimbo BP; Borrelli P; Pintor C; Cappa M
    J Clin Endocrinol Metab; 1995 Feb; 80(2):674-8. PubMed ID: 7852535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth hormone responses to GH-releasing peptide (GHRP-6) in hypothyroidism.
    Pimentel-Filho FR; Ramos-Dias JC; Ninno FB; Façanha CF; Liberman B; Lengyel AM
    Clin Endocrinol (Oxf); 1997 Mar; 46(3):295-300. PubMed ID: 9156038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction of the growth hormone releasing peptide hexarelin with somatostatin.
    Massoud AF; Hindmarsh PC; Brook CG
    Clin Endocrinol (Oxf); 1997 Nov; 47(5):537-47. PubMed ID: 9425393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth hormone/insulin-like growth factor-1 response to acute and chronic growth hormone-releasing peptide-2, growth hormone-releasing hormone 1-44NH2 and in combination in older men and women with decreased growth hormone secretion.
    Bowers CY; Granda-Ayala R
    Endocrine; 2001 Feb; 14(1):79-86. PubMed ID: 11322505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH.
    Arvat E; di Vito L; Maccagno B; Broglio F; Boghen MF; Deghenghi R; Camanni F; Ghigo E
    Peptides; 1997; 18(6):885-91. PubMed ID: 9285939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absence of growth hormone (GH) secretion after the administration of either GH-releasing hormone (GHRH), GH-releasing peptide (GHRP-6), or GHRH plus GHRP-6 in children with neonatal pituitary stalk transection.
    Pombo M; Barreiro J; Peñalva A; Peino R; Dieguez C; Casanueva FF
    J Clin Endocrinol Metab; 1995 Nov; 80(11):3180-4. PubMed ID: 7593423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of acute intravenous injection of two growth hormone-releasing hormones (GHRH 1-40 and 1-29) on serum growth hormone and other pituitary hormones in short children with pulsatile growth hormone secretion.
    Gelander L; Lindstedt G; Selstam G; Wide L; Albertsson-Wikland K
    Horm Res; 1989; 31(5-6):213-20. PubMed ID: 2515143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new test for the diagnosis of growth hormone deficiency due to primary pituitary impairment: combined administration of pyridostigmine and growth hormone-releasing hormone.
    Ghigo E; Imperiale E; Boffano GM; Mazza E; Bellone J; Arvat E; Procopio M; Goffi S; Barreca A; Chiabotto P
    J Endocrinol Invest; 1990 Apr; 13(4):307-16. PubMed ID: 2115060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth hormone (GH) responses to GH-releasing peptide and to GH-releasing hormone in GH-deficient children.
    Mericq V; Cassorla F; Garcia H; Avila A; Bowers CY; Merriam GR
    J Clin Endocrinol Metab; 1995 May; 80(5):1681-4. PubMed ID: 7745018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thyrotrophin and prolactin release in prolonged critical illness: dynamics of spontaneous secretion and effects of growth hormone-secretagogues.
    Van den Berghe G; de Zegher F; Veldhuis JD; Wouters P; Gouwy S; Stockman W; Weekers F; Schetz M; Lauwers P; Bouillon R; Bowers CY
    Clin Endocrinol (Oxf); 1997 Nov; 47(5):599-612. PubMed ID: 9425400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of selected endogenous peptides in growth hormone-releasing hexapeptide activity: analysis of growth hormone-releasing hormone, thyroid hormone-releasing hormone, and gonadotropin-releasing hormone.
    Bercu BB; Yang SW; Masuda R; Walker RF
    Endocrinology; 1992 May; 130(5):2579-86. PubMed ID: 1315249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Twenty-four-hour growth hormone (GH)-releasing peptide (GHRP) infusion enhances pulsatile GH secretion and specifically attenuates the response to a subsequent GHRP bolus.
    Huhn WC; Hartman ML; Pezzoli SS; Thorner MO
    J Clin Endocrinol Metab; 1993 May; 76(5):1202-8. PubMed ID: 8496311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.